Jonathan C. Trent, MD, PhD

Jonathan C. Trent, MD, PhD, a professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Angiosarcoma appears responsive to immune checkpoint inhibitors, says Trent. A study published in the

, immune checkpoint inhibitors resulted in an approximate 70% complete or partial response rate in patients with

Trent notes that patients with cutaneous angiosarcoma appear to have the most benefit from immunotherapy. However, pleomorphic sarcoma and the differentiated liposarcoma still have a lot of progress to be made in terms of bringing immunotherapy into the day-to-day management of patients with soft tissue sarcoma.

<< View more resources and information regarding sarcoma

Videos

Jonathan C. Trent, MD, PhD, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Immunotherapy Induces Responses in Subtypes of Sarcomas

Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).

View more from the Precision Medicine Special Report

Jonathan C. Trent, MD, PhD | Authors

Articles

Immunotherapy Induces Responses in Subtypes of Sarcomas

Significance of the NCI Molecular Analysis for Therapy Choice Program